Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Bicycle Therapeutics Yönetim
Yönetim kriter kontrolleri 4/4
Bicycle Therapeutics' CEO'su Kevin Lee, Sep2015 tarihinde atandı, in görev süresi 9.08 yıldır. in toplam yıllık tazminatı $ 5.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.8% maaş ve 87.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.37% ine doğrudan sahiptir ve bu hisseler $ 5.71M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 5.3 yıldır.
Anahtar bilgiler
Kevin Lee
İcra Kurulu Başkanı
US$5.5m
Toplam tazminat
CEO maaş yüzdesi | 12.8% |
CEO görev süresi | 9.1yrs |
CEO sahipliği | 0.4% |
Yönetim ortalama görev süresi | 3.6yrs |
Yönetim Kurulu ortalama görev süresi | 5.3yrs |
Son yönetim güncellemeleri
Recent updates
Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$165m |
Mar 31 2024 | n/a | n/a | -US$168m |
Dec 31 2023 | US$6m | US$710k | -US$181m |
Sep 30 2023 | n/a | n/a | -US$162m |
Jun 30 2023 | n/a | n/a | -US$140m |
Mar 31 2023 | n/a | n/a | -US$124m |
Dec 31 2022 | US$9m | US$673k | -US$113m |
Sep 30 2022 | n/a | n/a | -US$101m |
Jun 30 2022 | n/a | n/a | -US$87m |
Mar 31 2022 | n/a | n/a | -US$78m |
Dec 31 2021 | US$4m | US$677k | -US$67m |
Sep 30 2021 | n/a | n/a | -US$66m |
Jun 30 2021 | n/a | n/a | -US$62m |
Mar 31 2021 | n/a | n/a | -US$56m |
Dec 31 2020 | US$3m | US$592k | -US$51m |
Sep 30 2020 | n/a | n/a | -US$38m |
Jun 30 2020 | n/a | n/a | -US$37m |
Mar 31 2020 | n/a | n/a | -US$35m |
Dec 31 2019 | US$4m | US$517k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$33m |
Jun 30 2019 | n/a | n/a | -US$31m |
Mar 31 2019 | n/a | n/a | -US$26m |
Dec 31 2018 | US$818k | US$386k | -US$22m |
Tazminat ve Piyasa: Kevin 'ın toplam tazminatı ($USD 5.54M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.54M ).
Tazminat ve Kazançlar: Kevin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Kevin Lee (56 yo)
9.1yrs
Görev süresi
US$5,540,400
Tazminat
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Executive Director | 9.1yrs | US$5.54m | 0.37% $ 5.7m | |
Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.7m | |
Chief Financial Officer | 1.3yrs | US$2.88m | Veri yok | |
Chief Development Officer | 1.6yrs | US$2.82m | 0% $ 0 | |
Scientific Founder | no data | Veri yok | Veri yok | |
Chief Operating Officer | 2.8yrs | US$5.98m | 0.023% $ 354.4k | |
Senior VP | 1.3yrs | Veri yok | 0.0033% $ 51.1k | |
Chief Technology Officer | 2.8yrs | US$3.07m | 0.072% $ 1.1m | |
General Counsel | 4.5yrs | Veri yok | Veri yok | |
Head of Clinical and Project Management | 8.4yrs | Veri yok | Veri yok | |
Senior VP of Pre-Clinical Development | 5.9yrs | Veri yok | Veri yok | |
Chief Business Officer | 5.1yrs | US$1.40m | 0.012% $ 185.7k |
3.6yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: BCYC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Executive Director | 9.1yrs | US$5.54m | 0.37% $ 5.7m | |
Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.7m | |
Chairman of Scientific Advisory Board | 6.4yrs | Veri yok | Veri yok | |
Non-Executive Chairman | 5.6yrs | US$1.06m | 0.031% $ 485.0k | |
Independent Non-Executive Director | 3.6yrs | US$482.29k | 0.016% $ 242.5k | |
Independent Non-Executive Director | 5.3yrs | US$526.91k | 0.016% $ 242.5k | |
Member of Scientific Advisory Board | 4yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 4yrs | Veri yok | Veri yok | |
Independent Non-Executive Director | 5.3yrs | US$495.41k | 0.016% $ 242.5k | |
Member of Scientific Advisory Board | 6.4yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 4yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 4yrs | Veri yok | Veri yok |
5.3yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BCYC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).